BioNTech (NASDAQ:BNTX) Given New $139.00 Price Target at Morgan Stanley
BioNTech (NASDAQ:BNTX – Free Report) had its target price decreased by Morgan Stanley from $145.00 to $139.00 in a research note issued to investors on Tuesday morning,Benzinga reports. Morgan Stanley currently has an overweight rating on the stock. Other equities research analysts have also issued research reports about the stock. Canaccord Genuity Group reiterated a […]
BioNTech (NASDAQ:BNTX – Free Report) had its target price decreased by Morgan Stanley from $145.00 to $139.00 in a research note issued to investors on Tuesday morning,Benzinga reports. Morgan Stanley currently has an overweight rating on the stock. Other equities research analysts have also issued research reports about the stock. Canaccord Genuity Group reiterated a […]
